| Abstrakt: |
A recent report published in Cancer Weekly discusses the role of proteomic biomarkers in urogenital cancers, including prostate, bladder, and kidney malignancies. The study conducted a systematic review and meta-analysis of existing literature, identifying 1879 differentially expressed proteins from 37 studies. These proteins have the potential to serve as unique biomarkers for urogenital cancers and are involved in various biological processes. The findings highlight the importance of proteomics in understanding the molecular mechanisms of urogenital cancer and have the potential to improve patient care and clinical outcomes. For more information, readers can refer to the original article published in Cancers. [Extracted from the article] |
